Últimas noticias sobre Oryzon Genomics (OTC:ORYZF) Bolsa

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics SA

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

PATH

Needham Reiterates Hold on UiPathto Hold

Jefferies analyst Joseph Gallo upgrades SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Hold to Buy and raises the price target from $27 to $30.

Upgrades

Price Target

Jefferies Upgrades SentinelOne to Buy, Raises Price Target to $30

BP1001-A downregulates growth factor receptor-bound protein 2 (Grb2) expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggeststhat by downregulating Grb2 expression, BP1001-A&nbsp;could help lower blood glucose level by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes.&nbsp;&nbsp; The study results showed:
<ul>
<li>BP1001-A reduced Grb2 protein expression in myoblast cells</li>
<li>BP1001-A increased the levels of phosphorylated AKT and phosphorylated FOXO-1 in myoblast and hepatoma cells in the presence of insulin</li>
</ul>
These initial data confirmed that by downregulating Grb2 expression, BP1001-A could enhance insulin-induced metabolic events by affecting the insulin/phosphoinositol-3 kinase (PI3K)/AKT pathway and increase insulin sensitivity.&nbsp;

Biotech

Health Care

General

BPTH

Bio-Path Reported That Results From Preclinical Studies Of BP1001-A For Obesity Demonstrated Enhanced Insulin Sensitivity, Confirming BP1001-A As A Potential Treatment For Obesity And Related Metabolic Diseases In Type 2 Diabetes Patients

WIIM

Bio-Path Holdings shares are trading higher after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.

MNMD

MindMed To Be Added To The Nasdaq Biotechnology Index, Effective At Market Open On December 23, 2024

Contracts

VRAR

The Glimpse Group shares are trading higher after its subsidiary, Brightline Interactive, announced a six-figure contract with the U.S. Navy for an immersive simulator.

ACET

Adicet Bio Says First Patient Dosed In The Phase 1 Clinical Trial Evaluating ADI-270 In Patients With Metastatic/Advanced ccRCC

The Glimpse Group's Subsidiary Company Brightline Interactive Has Entered Into An Initial Six Figure Dollar Contract With The U.S. Navy For An Immersive Simulator, To Be Delivered In The First Half Of 2025

Jefferies analyst Michael Yee downgrades ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Buy to Hold and lowers the price target from $12 to $2.

Downgrades

ALXO

Jefferies Downgrades ALX Oncology Holdings to Hold, Lowers Price Target to $2

Fiscal 2025 Expectations
•Organic ASV is expected to grow in the range of $90 million to $140 million during fiscal 2025.
•GAAP revenues are expected to be in the range of $2,285 million to $2,305 million.
•GAAP operating margin is expected to be in the range of 32.5% to 33.5%.
•Adjusted operating margin is expected to be in the range of 36.0% to 37.0%.
•FactSet's annual effective tax rate is expected to be in the range of 17% to 18%.
•GAAP diluted EPS is expected to be in the range of $15.10 to $15.70.
•Adjusted diluted EPS is expected to be in the range of $16.80 to $17.40.

Earnings

Guidance

FactSet Reaffirms FY25 Guidance: Sees Revenues Of $2.285B - $2.305B Vs. $2.301B Est., And Adjusted EPS Of $16.80 - $17.40 Vs. $17.17 Est.

HC Wainwright &amp; Co. analyst Sean Lee reiterates Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and maintains $7 price target.

VSTM

HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $7 Price Target

LASE

Laser Photonics Receives Dual Order From Oil Refiner Phillips 66 For CleanTech And MarkStar Laser Systems; No Terms Disclosed

In addition to the Fast Track designation announced today for Waldenstrom's macroglobulinemia, NX-5948 previously received Fast Track designation in January 2024 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.

NRIX

Nurix Says FDA Granted Fast Track Designation For NX-5948 For Treatment Of Adult Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia After At Least Two Lines Of Therapy

Jefferies analyst Samad Samana upgrades Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) from Hold to Buy and raises the price target from $85 to $100.

Jefferies Upgrades Zoom Communications to Buy, Raises Price Target to $100

Management

LXEO

Lexeo Therapeutics Appoints Dr. Kyle Rasbach As Chief Financial Officer, Effective Immediately.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Uranium Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UROY#NASDAQ">UROY</a>) with a Buy and maintains $7.7 price target.

UROY

HC Wainwright & Co. Reiterates Buy on Uranium Royalty, Maintains $7.7 Price Target

REGN7508 (catalytic domain) is designed to maximize anticoagulant activity while minimizing bleeding risk, and REGN9933 (A2 domain) is designed to provide an additional option for patients with the highest bleeding risk who would otherwise not be candidates for currently available anticoagulants.&nbsp;
Per the Phase 2 results, there was an antithrombotic effect for each antibody, and no clinically relevant bleeding was observed in any treatment arm.

REGN

Regeneron Reports Phase 2 Results For Two Novel Monoclonal Antibodies Targeting Distinct Domains Of Factor XI; Says There Was Antithrombotic Effect For Each Antibody; Phase 3 Program To Be Initiated In 2025

Fiscal 2025 Financial Outlook The Company updated its full year financial outlook for fiscal 2025 which now includes Chuy's operating results, but excludes approximately $47 million, pre-tax, of expected transaction and integration related costs associated with the acquisition. The Company will provide additional details during its investor conference call scheduled for this morning at 8:30 am ET.
<ul>
<li>Total sales of approximately $12.1 billion</li>
<li>Same-restaurant sales growth of approximately 1.5%&#x2A;</li>
<li>New restaurant openings of 50 to 55</li>
<li>Total capital spending of approximately $650 million</li>
<li>Total inflation of approximately 2.5%</li>
<li>An effective tax rate of approximately 12.5%</li>
<li>Diluted net earnings per share from continuing operations of $9.40 to $9.60, excluding approximately $47 million, pre-tax, of Chuy's transaction and integration related costs&#x2A;&#x2A;</li>
<li>Approximately 118 million weighted average diluted shares outstanding</li>
</ul>

Restaurants

Darden Restaurants Expects 2025 Sales Of Approximately $12.1B Vs. Consensus Of $12.084B

Jefferies analyst Samad Samana downgrades NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) from Buy to Hold and lowers the price target from $215 to $200.

NICE

Jefferies Downgrades NICE to Hold, Lowers Price Target to $200

<ul>
<li>Same-restaurant sales:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Consolidated Darden&#x2A;</td>
<td colspan="1" rowspan="1">2.4&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Olive Garden</td>
<td colspan="1" rowspan="1">2.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">LongHorn Steakhouse</td>
<td colspan="1" rowspan="1">7.5&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Fine Dining&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">(5.8)&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Other Business&#x2A;</td>
<td colspan="1" rowspan="1">0.7&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

Comments

Oryzon Genomics

Noticias

Últimas noticias sobre Oryzon Genomics (OTC:ORYZF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL